Vascular protection in peripheral artery disease: Systematic review and modelling study

Heart

Volumn 95, Issue 13, 2009, Pages 1098-1102

  Hackam, D G ^a,d   Sultan, N M ^b   Criqui, M H ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Stroke Prevention and Atherosclerosis Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE;

ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; DIET SUPPLEMENTATION; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; EXERCISE; HEART INFARCTION; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; MATHEMATICAL MODEL; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; VASCULAR SURGERY;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, STATISTICAL; PERIPHERAL VASCULAR DISEASES; SENSITIVITY AND SPECIFICITY;

EID: 67649595710     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.161554     Document Type: Article

References (28)

1. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3. (Pubitemid 34756482)
2. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189 (Pubitemid 43076437)
3. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-239 (Pubitemid 40216240)
4. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002;166:333-339 (Pubitemid 34864422)
5. Mohiuddin SM, Mooss AN, Hunter CB, et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest 2007;131:446-452 (Pubitemid 46280405)
6. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97. (Pubitemid 37432870)
7. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000;160:939-944 (Pubitemid 30191921)
8. Willigendael EM, Teijink JA, Bartelink ML, et al. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg 2005;42:67-74. (Pubitemid 40966078)
9. Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial (and meta-analysis). J Intern Med 2007;261:276-284 (Pubitemid 46255949)
10. Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007;(4):CD000123. (Pubitemid 351805279)
11. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24. (Pubitemid 38055588)
12. Thatipelli MR, Pellikka PA, McBane RD, et al. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. J Vasc Surg 2007;46:62-70. (Pubitemid 46990758)
13. Hooi JD, Stoffers HEJH, Knottnerus JA, et al. The prognosis of non-critical limb ischaemia: a systematic review of population-based evidence. Br J Gen Pract 1999;49:49-55. (Pubitemid 29027504)
14. Hooi JD, Stoffers HE, Kester AD, et al. Peripheral arterial occlusive disease: prognostic value of signs, symptoms, and the ankle-brachial pressure index. Med Decis Making 2002;22:99-107. (Pubitemid 34246125)
15. Dormandy JA, Murray GD. The fate of the claudicant - a prospective study of 1969 claudicants. Eur J Vasc Surg 1991;5:131-133
16. Smith FB, Rumley A, Lee AJ, et al. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998;100:758-763 (Pubitemid 28126111)
17. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-892 (Pubitemid 36519734)
18. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15. (Pubitemid 44406838)
19. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl J Med 2006;;354:1706-1717
20. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New Engl J Med 2004;351:2058-2068 (Pubitemid 39482499)
21. TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial. The Lancet 2008;372:1174-1183
22. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339 (Pubitemid 26383772)
23. Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107:753-756 (Pubitemid 36222605)
24. CREDO Investigators. Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. Heart 2006;92:49-51. (Pubitemid 43021852)
25. Brass EP, Hiatt WR. Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies. Vasc Med 2006;11:141-145 (Pubitemid 46099257)
26. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med 2003;348:383-393 (Pubitemid 36159355)
27. Rachmani R, Slavachevski I, Berla M, et al. Teaching and motivating patients to control their risk factors retards progression of cardiovascular as well as microvascular sequelae of Type 2 diabetes mellitus - a randomized prospective 8 years follow-up study. Diabet Med 2005;22:410-414 (Pubitemid 40516239)
28. Joss N, Ferguson C, Brown C, et al. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 2004;97:219-227 (Pubitemid 38489162)